

Drug resistance interpretation: PR		HIVDB 9.5.1 (2023-11-05)
PI Major Mutations:	None	
PI Accessory Mutations:	None	
PR Other Mutations:	L19I <small>100% seen=62,636</small> • R41K <small>99% seen=26,579</small> • L63Q <small>100% seen=22,973</small> • I64V <small>100% seen=22,973</small> • C67C5 <small>0-10% seen=22,999</small> S-37% • V77I <small>100% seen=21,765</small>	
Protease Inhibitors		
atazanavir/r (ATV/r)	Susceptible	
darunavir/r (DRV/r)	Susceptible	
fosamprenavir/r (FPV/r)	Susceptible	
indinavir/r (IDV/r)	Susceptible	
lopinavir/r (LPV/r)	Susceptible	
nelfinavir (NFV)	Susceptible	
saquinavir/r (SQV/r)	Susceptible	
tipranavir/r (TPV/r)	Susceptible	
Mutation scoring: PR		HIVDB 9.5.1 (2023-11-05)

Drug resistance interpretation: RT		HIVDB 9.5.1 (2023-11-05)	
NRTI Mutations:		M184V 99% <small>seen=103</small>	
NNRTI Mutations:		None	
RT Other Mutations:		I5V 99% <small>seen=2K,295</small> • V35T 97% <small>seen=123</small> • T39R 99% <small>seen=302</small> • V60I 99% <small>seen=402</small> • D121Y 100% <small>seen=1302</small> • K122E 99% <small>seen=302</small> • D123E 99% <small>seen=302</small> • I135T 100% <small>seen=194</small> • I142V 97% <small>seen=130</small> • S162C 100% <small>seen=171</small> • K173R 99% <small>seen=109</small> • D177E 100% <small>seen=547</small> • I178IM 91-92% <small>seen=130</small> S-10% • Q207E 99% <small>seen=535</small> • R211K 100% <small>seen=545</small> • V245E 99% <small>seen=544</small> • D250E 99% <small>seen=542</small> • T286A 100% <small>seen=137</small> • I293V 99% <small>seen=130</small> • E297K 99% <small>seen=138</small> • G335D 100% <small>seen=88</small> • R356K 100% <small>seen=105</small> • M357K 99% <small>seen=55</small> • A360T 100% <small>seen=105</small> • T377Q 100% <small>seen=123</small> • S379C 100% <small>seen=105</small> • K390R 99% <small>seen=102</small> • K395R 99% <small>seen=12</small> • A400T 99% <small>seen=55</small> • K512N 100% <small>seen=1,323</small> • S519N 100% <small>seen=1,364</small> • A534S 99% <small>seen=1,385</small> •	
A534S 99% <small>seen=1,385</small>			
Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Low-Level Resistance	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Potential Low-Level Resistance	nevirapine (NVP)	Susceptible
emtricitabine (FTC)	High-Level Resistance	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	High-Level Resistance		
tenofovir (TDF)	Susceptible		
RT comments			
NRTI			
<ul style="list-style-type: none">M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.			

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

Drug resistance mutation scores of NRTI:

Download CSV

Rule	ABC	AZT	D4T	DDI	FTC	3TC	TDF
M184V	15	-10	-10	10	60	60	-10

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN		HIVDB 9.5.1 (2023-11-05)
INSTI Major Mutations:	None	
INSTI Accessory Mutations:	None	
IN Other Mutations:	K14R 99% <small>seen=1,356</small> • V31I 100% <small>seen=932</small> • T93TA 7-10% <small>seen=110</small> S-10% • T112V 100% <small>seen=417</small> • I113V 100% <small>seen=438</small> • S119T 100% <small>seen=711</small> • T124A 100% <small>seen=782</small> • T125A 100% <small>seen=782</small> • V126F 99% <small>seen=782</small> • K127K/R 9-10% <small>seen=1,294</small> S-12% • G134N 100% <small>seen=1,408</small> • I135V 100% <small>seen=1,408</small> • K136Q 100% <small>seen=1,408</small> • F139Y 100% <small>seen=1,784</small> • D167E 99% <small>seen=2,152</small> • V201I 100% <small>seen=1,126</small> • K211R 99% <small>seen=1,038</small> • Q216H 100% <small>seen=2,951</small> • T218L 99% <small>seen=2,808</small> • F223Y 100% <small>seen=2,921</small> • A263V 100% <small>seen=3,522</small> • D278A 100% <small>seen=2,802</small> • S283G 100% <small>seen=2,883</small>	
Integrase Strand Transfer Inhibitors		
bictegravir (BIC)	Susceptible	
cabotegravir (CAB)	Susceptible	
dolutegravir (DTG)	Susceptible	
elvitegravir (EVG)	Susceptible	
raltegravir (RAL)	Susceptible	
Mutation scoring: IN		HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for INSTI.		